{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:21Z","timestamp":1791497601204,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.respe.2016.06.335","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T09:01:18Z","timestamp":1481706078000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anti\u00e9m\u00e9tiques et effets cardiaques potentiellement li\u00e9s \u00e0 un allongement de l\u2019intervalle QT\u00a0: analyse cas\/non-cas dans la Base nationale de pharmacovigilance"],"prefix":"10.1016","volume":"65","author":[{"given":"M.","family":"Rochoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Auffret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.respe.2016.06.335_bib0210","series-title":"EMC Trait\u00e9 M\u00e9decine AKOS","first-page":"1","article-title":"Naus\u00e9es et vomissements\u00a0: du sympt\u00f4me au diagnostic","author":"Pariente","year":"2011"},{"key":"10.1016\/j.respe.2016.06.335_bib0215","series-title":"Ventes de m\u00e9dicaments en France\u00a0: le rapport d\u2019analyse de l\u2019ann\u00e9e 2013 [Internet]","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2014"},{"issue":"9","key":"10.1016\/j.respe.2016.06.335_bib0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/pds.2016","article-title":"Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study","volume":"19","author":"Johannes","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"19","key":"10.1016\/j.respe.2016.06.335_bib0225","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"26","author":"Straus","year":"2005","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.respe.2016.06.335_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000083234","article-title":"Comparison of the effects of metoclopramide and domperidone on HERG channels","volume":"74","author":"Claassen","year":"2005","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.respe.2016.06.335_bib0235","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/FJC.0b013e31827afd0d","article-title":"Domperidone: limited benefits with significant risk for sudden cardiac death","volume":"61","author":"Hondeghem","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8451","key":"10.1016\/j.respe.2016.06.335_bib0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(85)92515-2","article-title":"Cardiotoxicity of intravenous domperidone","volume":"326","author":"Osborne","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.respe.2016.06.335_bib0245","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2014"},{"key":"10.1016\/j.respe.2016.06.335_bib0250","series-title":"De nouvelles recommandations pour minimiser les risques cardiaques des m\u00e9dicaments contenant de la domp\u00e9ridone [Internet]","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2014"},{"issue":"7","key":"10.1016\/j.respe.2016.06.335_bib0255","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-150-7-200904070-00016","article-title":"Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency","volume":"150","author":"Siddique","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.respe.2016.06.335_bib0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/DCT-200064482","article-title":"The phenothiazine drugs inhibit hERG potassium channels","volume":"28","author":"Kim","year":"2005","journal-title":"Drug Chem Toxicol"},{"issue":"6","key":"10.1016\/j.respe.2016.06.335_bib0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2044.2009.05890.x","article-title":"Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study","volume":"64","author":"Owczuk","year":"2009","journal-title":"Anaesthesia"},{"issue":"5","key":"10.1016\/j.respe.2016.06.335_bib0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":"Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database","volume":"44","author":"Moore","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.respe.2016.06.335_bib0275","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"issue":"6","key":"10.1016\/j.respe.2016.06.335_bib0280","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.respe.2016.06.335_bib0285","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"issue":"3","key":"10.1016\/j.respe.2016.06.335_bib0290","first-page":"373","article-title":"[Method for determination of undesirable effects of drugs]","volume":"33","author":"Dangoumau","year":"1978","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.respe.2016.06.335_bib0295","first-page":"111","article-title":"[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"issue":"8","key":"10.1016\/j.respe.2016.06.335_bib0300","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"10.1016\/j.respe.2016.06.335_bib0305","series-title":"Rupture de stock de VOGALENE (m\u00e9topimazine) [Internet]","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)","year":"2014"},{"issue":"8","key":"10.1016\/j.respe.2016.06.335_bib0310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.respe.2016.06.335_bib0315","first-page":"537","article-title":"The effect of phenothiazines on the electrocardiogram","volume":"91","author":"Ban","year":"1964","journal-title":"Can Med Assoc J"},{"issue":"4\u00a0Pt 2","key":"10.1016\/j.respe.2016.06.335_bib0320","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0755-4982(06)74665-6","article-title":"[Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval]","volume":"35","author":"Trojak","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.respe.2016.06.335_bib0325","series-title":"Drugs that prolong the QT interval and\/or induce torsades de pointes ventricular arrhythmia [Internet]","author":"The University of Arizona Center for Education and Research on Therapeutics","year":"2014"},{"issue":"3","key":"10.1016\/j.respe.2016.06.335_bib0330","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2125.2008.03249.x","article-title":"Cisapride and ventricular arrhythmia","volume":"66","author":"Hennessy","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.respe.2016.06.335_bib0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01249-0","article-title":"A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG","volume":"417","author":"Rampe","year":"1997","journal-title":"FEBS Lett"},{"issue":"16","key":"10.1016\/j.respe.2016.06.335_bib0340","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.102.16.1883","article-title":"Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders","volume":"102","author":"Drolet","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.respe.2016.06.335_bib0345","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2125.2006.02722.x","article-title":"In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs","volume":"63","author":"De Bruin","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"129","key":"10.1016\/j.respe.2016.06.335_bib0350","first-page":"183","article-title":"Domperidone: ventricular arrhythmia and sudden death (continued)","volume":"21","year":"2012","journal-title":"Prescrire Int"},{"issue":"11","key":"10.1016\/j.respe.2016.06.335_bib0355","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/11536840-000000000-00000","article-title":"Domperidone and ventricular arrhythmia or sudden cardiac death","volume":"33","author":"Noord van","year":"2010","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.respe.2016.06.335_bib0360","first-page":"805","article-title":"Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block","volume":"24","author":"Chou","year":"2001","journal-title":"Chang Gung Med J"},{"issue":"1","key":"10.1016\/j.respe.2016.06.335_bib0365","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0022-3565(24)35285-1","article-title":"Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions","volume":"292","author":"Crumb","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.respe.2016.06.335_bib0370","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2008.05.009","article-title":"The hERG potassium channel and hERG screening for drug-induced torsades de pointes","volume":"119","author":"Hancox","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.respe.2016.06.335_bib0375","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1540-8167.1999.tb00224.x","article-title":"Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current","volume":"10","author":"Drolet","year":"1999","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7","key":"10.1016\/j.respe.2016.06.335_bib0380","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bjp.2008.191","article-title":"Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines","volume":"154","author":"Lu","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.respe.2016.06.335_bib0385","series-title":"Martindale: the complet drug reference","article-title":"M\u00e9topimazine","author":"Sweetman","year":"2011"},{"issue":"2","key":"10.1016\/j.respe.2016.06.335_bib0390","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0022-3565(24)38946-3","article-title":"Interactions of the 5-hydroxytryptamine 3\u00a0antagonist class of antiemetic drugs with human cardiac ion channels","volume":"295","author":"Kuryshev","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.respe.2016.06.335_bib0395","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","article-title":"Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron","volume":"102","author":"Charbit","year":"2005","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.respe.2016.06.335_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis","volume":"64","author":"Freedman","year":"2014","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.respe.2016.06.335_bib0405","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.phrs.2009.05.008","article-title":"H1\u00a0antihistamine drug promethazine directly blocks hERG K+ channel","volume":"60","author":"Jo","year":"2009","journal-title":"Pharmacol Res"},{"issue":"13","key":"10.1016\/j.respe.2016.06.335_bib0205","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"}],"container-title":["Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398762016308112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398762016308112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:38:37Z","timestamp":1759970317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0398762016308112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0398762016308112"],"URL":"https:\/\/doi.org\/10.1016\/j.respe.2016.06.335","relation":{},"ISSN":["0398-7620"],"issn-type":[{"value":"0398-7620","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u00e9m\u00e9tiques et effets cardiaques potentiellement li\u00e9s \u00e0 un allongement de l\u2019intervalle QT\u00a0: analyse cas\/non-cas dans la Base nationale de pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.respe.2016.06.335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}